Home/Filings/4/0001209191-14-046073
4//SEC Filing

Forest Laboratories, LLC 4

Accession 0001209191-14-046073

CIK 0000038074operating

Filed

Jul 2, 8:00 PM ET

Accepted

Jul 3, 5:13 PM ET

Size

68.4 KB

Accession

0001209191-14-046073

Insider Transaction Report

Form 4
Period: 2014-07-01
Francis Perier I Jr
SVP Finance & CFO
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-0111,1750 total
    Exercise: $44.74Exp: 2014-09-30Common stock (11,175 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-012,4820 total
    Exercise: $40.29Exp: 2015-12-09Common stock (2,482 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-011,9400 total
    Exercise: $51.54Exp: 2016-12-08Common stock (1,940 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-0145,8550 total
    Exercise: $24.12Exp: 2018-12-08Common stock (45,855 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-0156,8020 total
    Exercise: $31.27Exp: 2019-12-06Common stock (56,802 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-0175,0000 total
    Exercise: $31.27Exp: 2020-12-05Common stock (75,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-0165,1880 total
    Exercise: $37.88Exp: 2023-05-20Common stock (65,188 underlying)
  • Award

    Performance Stock Units

    2014-07-01+32,63632,636 total
    Exercise: $0.00Common stock (32,636 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-0188,8250 total
    Exercise: $44.74Exp: 2014-09-30Common stock (88,825 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-0173,0600 total
    Exercise: $51.54Exp: 2016-12-08Common stock (73,060 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-012,6840 total
    Exercise: $37.26Exp: 2017-12-05Common stock (2,684 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-0147,5180 total
    Exercise: $40.29Exp: 2015-12-09Common stock (47,518 underlying)
  • Disposition to Issuer

    Common Stock

    2014-07-0162,0710 total
  • Disposition to Issuer

    Restricted Stock

    2014-07-0123,5800 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-0147,3160 total
    Exercise: $37.26Exp: 2017-12-05Common stock (47,316 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-014,1450 total
    Exercise: $24.12Exp: 2018-12-08Common stock (4,145 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-012,6400 total
    Exercise: $37.88Exp: 2023-05-20Common stock (2,640 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-013,1980 total
    Exercise: $31.27Exp: 2019-12-06Common stock (3,198 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-013,3330 total
    Exercise: $30.00Exp: 2021-12-04Common stock (3,333 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-0171,6670 total
    Exercise: $30.00Exp: 2021-12-04Common stock (71,667 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-012,9380 total
    Exercise: $34.04Exp: 2022-05-06Common stock (2,938 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-07-0131,0180 total
    Exercise: $34.04Exp: 2022-05-06Common stock (31,018 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2014-07-0118,6320 total
    Exercise: $0.00Common stock (18,632 underlying)
  • Award

    Performance Stock Units

    2014-07-01+18,63218,632 total
    Exercise: $0.00Common stock (18,632 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2014-07-0132,6360 total
    Exercise: $0.00Common stock (32,636 underlying)
Footnotes (24)
  • [F1]Each share of common stock was disposed of pursuant to the Merger Agreement, dated as of February 17, 2014 (the "Merger Agreement"), by and among the issuer and Actavis plc ("Actavis"), Tango US Holdings Inc., Tango Merger Sub 1 LLC, and Tango Merger Sub 2 LLC in exchange for either (A) $26.04 in cash plus 0.3306 Actavis ordinary shares having a market value of $224 per share on the effective date of the merger or (B) $25.67 in cash plus 0.332623 Actavis ordinary shares having a market value of $224 per share on the effective date of the merger, depending on the consideration election made by the reporting person and the consideration election proration procedures set forth in the Merger Agreement.
  • [F10]The options, which are currently exercisable, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F11]The options, which are currently exercisable, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F12]The options, which are currently exercisable, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F13]The options, which vest on December 7, 2014, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F14]The options, 36,000 of which are currently exercisable and 20,802 of which vest on December 7, 2014, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F15]The options, which are currently exercisable, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F16]The options, which vest on December 5, 2015, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F17]The options, 37,500 of which are currently exercisable, 18,750 of which vest on December 5, 2014, and 15,417 of which vest on December 5, 2015, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F18]The options, which vest on May 7, 2016, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F19]The options, 16,978 of which are currently exercisable, 8,489 of which vest on May 7, 2015, and 5,551 of which vest on May 7, 2016, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F2]Outstanding restricted stock awards were assumed by Actavis pursuant to the Merger Agreement and replaced with an Actavis restricted stock unit award covering 0.4723 Actavis ordinary shares having a market value of $224 per share on the effective date of the merger for each issuer share underlying the restricted stock award.
  • [F20]The options, which vest on May 21, 2017, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F21]The options, 16,957 of which are currently exercisable, 16,957 of which vest on May 21, 2015, 16,957 of which vest on May 21, 2016, and 14,317 of which vest on May 21, 2017, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F22]The performance conditions with respect to the issuer performance stock unit award were deemed to be earned based on target performance as of the effective time of the transaction, and the performance stock unit award (as so earned) will vest on April 1, 2015, subject to the reporting person's continued employment through such date and also to acceleration in the event of certain terminations of employment.
  • [F23]The performance conditions with respect to the issuer performance stock unit award were deemed to be earned based on target performance as of the effective time of the transaction, and the performance stock unit award (as so earned) will vest on April 1, 2016, subject to the reporting person's continued employment through such date and also to acceleration in the event of certain terminations of employment.
  • [F24]Each outstanding performance stock unit award (as deemed earned pursuant to the Merger Agreement) was assumed by Actavis pursuant to the Merger Agreement and replaced with an Actavis restricted stock unit award covering 0.4723 Actavis ordinary shares having a market value of $224.00 per share on the effective date of the merger for each issuer share underlying the performance stock unit award.
  • [F3]The options, which are currently exercisable, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F4]The options, which are currently exercisable, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F5]The options, which are currently exercisable, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F6]The options, which are currently exercisable, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F7]The options, which are currently exercisable, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F8]The options, which are currently exercisable, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
  • [F9]The options, which are currently exercisable, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.

Issuer

Forest Laboratories, LLC

CIK 0000038074

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000038074

Filing Metadata

Form type
4
Filed
Jul 2, 8:00 PM ET
Accepted
Jul 3, 5:13 PM ET
Size
68.4 KB